Our Laboratory of Immunology at the Institute of Nutritional Medicine at the University of Lübeck and the University Hospital Schleswig-Holstein ( https://www.uksh.de/Ernaehrungsmedizin_Luebeck/ ) is investigating different stages of allergy and allergen-specific therapy. It has been observed that, in addition to allergic individuals, a certain proportion of healthy individuals express allergen-specific IgE antibodies. Some of these sensitised healthy individuals may develop allergy or worse, asthma, over time, but most are unlikely to ever develop allergic disease. In addition, allergen-specific immunotherapy to induce protective IgG antibodies works in some, but not all, patients. The increasingly accepted hypothesis is that different (inflammatory) T and B cell responses leading to different antibody compositions (including qualitatively different IgE antibodies with different IgE glycosylation forms) are responsible for these different phenomena and that the transition between these different immune states is dynamic in both directions (worse or better). Publications can be found at ORCID (0000-0002-5383-8603) and Scopus (7102012162). Some selected studies: (Oefner et al, JACI 2012, doi: 10.1016/j.jaci.2012.02.037; Karsten et al, Nature Medicine 2012, doi: 10.1038/nm.2862; Strait et al, Nature 2015, doi: 10.1038/nature13868.; Bartsch et al, JACI 2020, doi: 10.1016/j.jaci.2020.04.059; Petry et al, JACI 2021, doi: 10.1016/j.jaci.2020.05.056; Buhre et al, FI 2023, doi: 10.3389/fimmu.2022.1020844; Dühring et al, Allergy 2023, doi: 10.1111/all.15665; Buhre et al, Allergy 2025, doi: 10.1111/all.16241). We want to compare different stages of allergy and therapy using antibody composition analysis, including antibody ELISA and glycosylation analysis, and T and B cell analysis. We are looking for a highly motivated PhD student. The candidate should have completed a relevant study. We are a highly motivated team with a good atmosphere. The candidtae could become a member of a newly approved Research Training Group of the DFG.